Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin in Primary Sclerosing Cholangitis
NCT02978339Phase 2Completed
- Start
- Jun 2017
- Primary completion
- Nov 2018
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of curcumin in Primary Sclerosing Cholangitis (PSC). Primary endpoint: Serum Alkaline Phosphatase at 12 weeks. Started Jun 2017; status: completed.
02
Drugs
curcumin
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT02978339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978339.